Treace Medical Concepts (TMCI) Financials

$5.90 +0.06 (+0.94%)

As of 10:23 AM Eastern

Annual Income Statements for Treace Medical Concepts

This table shows Treace Medical Concepts' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-56	-49	-43
Consolidated Net Income / (Loss)	-56	-50	-43
Net Income / (Loss) Continuing Operations	-56	-50	-43
Total Pre-Tax Income	-56	-50	-43
Total Operating Income	-56	-51	-35
Total Gross Profit	168	152	116
Total Revenue	209	187	142
Operating Revenue	209	187	142
Total Cost of Revenue	41	35	26
Operating Cost of Revenue	41	35	26
Total Operating Expenses	224	203	151
Selling, General & Admin Expense	56	47	33
Marketing Expense	148	141	105
Research & Development Expense	21	15	14
Other Operating Expenses / (Income)	-0.32	-0.34	-
Total Other Income / (Expense), net	-0.50	1.90	-7.97
Interest Expense	5.26	5.17	8.88
Interest & Investment Income	4.88	6.73	1.31
Other Income / (Expense), net	-0.12	-	-0.40
Basic Earnings per Share	($0.90)	($0.81)	($0.77)
Weighted Average Basic Shares Outstanding	62.11M	60.85M	55.28M
Diluted Earnings per Share	($0.90)	($0.81)	($0.77)
Weighted Average Diluted Shares Outstanding	62.11M	60.85M	55.28M
Weighted Average Basic & Diluted Shares Outstanding	62.62M	61.76M	61.16M

This table shows Treace Medical Concepts' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-0.50	-15	-21	-19	-5.97	-17	-12	-13	-8.11	-12
Consolidated Net Income / (Loss)	-0.50	-15	-21	-19	-6.28	-18	-12	-13	-4.41	-12
Net Income / (Loss) Continuing Operations	-1.01	-15	-21	-19	-6.51	-18	-12	-13	-8.13	-12
Total Pre-Tax Income	-1.01	-15	-21	-19	-6.51	-18	-12	-13	-8.13	-12
Total Operating Income	-0.20	-15	-21	-19	-6.78	-18	-13	-14	-3.50	-11
Total Gross Profit	55	36	36	41	51	33	34	34	41	27
Total Revenue	69	45	44	51	62	41	42	42	50	33
Operating Revenue	69	45	44	51	62	41	42	42	50	33
Total Cost of Revenue	13	8.95	8.78	10	11	8.00	7.68	8.04	9.02	6.09
Operating Cost of Revenue	13	8.95	8.78	10	11	8.00	7.68	8.04	9.02	6.09
Total Operating Expenses	56	51	57	60	57	51	47	48	44	38
Selling, General & Admin Expense	14	14	14	14	13	13	10	11	10	8.92
Marketing Expense	37	33	38	40	40	34	34	34	30	26
Research & Development Expense	5.21	4.96	5.16	5.26	4.15	4.35	3.53	3.41	3.75	3.80
Other Operating Expenses / (Income)	-0.12	-0.02	-0.11	-0.07	-	-0.02	-0.10	-	-	0.05
Total Other Income / (Expense), net	-0.81	-0.26	0.15	0.42	0.50	0.30	0.78	0.32	-4.58	-0.82
Interest Expense	1.31	1.31	1.31	1.32	1.30	1.30	1.28	1.29	10	1.19
Interest & Investment Income	0.90	1.07	1.38	1.54	1.71	1.57	1.97	1.48	0.75	0.42
Other Income / (Expense), net	-0.39	-0.01	0.08	0.20	-	-	-	0.13	-	-
Basic Earnings per Share	($0.01)	($0.25)	($0.34)	($0.30)	($0.10)	($0.28)	($0.20)	($0.23)	($0.08)	($0.22)
Weighted Average Basic Shares Outstanding	62.11M	62.23M	62.08M	61.79M	60.85M	61.56M	61.38M	58.72M	55.28M	55.43M
Diluted Earnings per Share	($0.01)	($0.25)	($0.34)	($0.30)	($0.10)	($0.28)	($0.20)	($0.23)	($0.08)	($0.22)
Weighted Average Diluted Shares Outstanding	62.11M	62.23M	62.08M	61.79M	60.85M	61.56M	61.38M	58.72M	55.28M	55.43M
Weighted Average Basic & Diluted Shares Outstanding	62.62M	62.30M	62.19M	62.01M	61.76M	61.68M	61.54M	61.33M	61.16M	55.50M

This table details how cash moves in and out of Treace Medical Concepts' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	-1.63	-6.49	-86
Net Cash From Operating Activities	-37	-35	-31
Net Cash From Continuing Operating Activities	-37	-35	-31
Net Income / (Loss) Continuing Operations	-56	-50	-43
Consolidated Net Income / (Loss)	-56	-50	-43
Depreciation Expense	8.42	5.35	2.13
Amortization Expense	-0.85	-1.11	0.12
Non-Cash Adjustments To Reconcile Net Income	34	20	16
Changes in Operating Assets and Liabilities, net	-23	-9.74	-5.81
Net Cash From Investing Activities	35	-81	-77
Net Cash From Continuing Investing Activities	35	-81	-77
Purchase of Property, Plant & Equipment	-12	-11	-15
Acquisitions	0.00	-20	0.00
Purchase of Investments	-72	-170	-63
Sale and/or Maturity of Investments	119	120	1.73
Net Cash From Financing Activities	0.16	109	21
Net Cash From Continuing Financing Activities	0.16	109	21
Repayment of Debt	0.00	0.00	-0.99
Issuance of Debt	0.00	0.00	50
Issuance of Common Equity	0.00	108	0.00
Other Financing Activities, net	0.16	1.86	-28
Cash Interest Paid	4.96	5.17	4.40

This table details how cash moves in and out of Treace Medical Concepts' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-0.76	-6.07	8.85	-3.65	5.70	-4.76	-18	10	-69	-4.29
Net Cash From Operating Activities	-4.21	-12	-14	-7.22	0.53	-9.51	-8.34	-17	-5.36	-7.48
Net Cash From Continuing Operating Activities	-4.21	-12	-14	-7.22	0.53	-9.51	-8.47	-17	-5.65	1.51
Net Income / (Loss) Continuing Operations	-0.50	-15	-21	-19	-6.28	-18	-12	-13	-4.41	-12
Consolidated Net Income / (Loss)	-0.50	-15	-21	-19	-6.28	-18	-12	-13	-4.41	-12
Depreciation Expense	2.24	2.16	2.12	1.91	1.77	1.56	1.10	0.92	0.92	0.46
Amortization Expense	-0.15	-0.16	-0.28	-0.26	-0.30	-0.29	-0.29	-0.22	-0.05	0.07
Non-Cash Adjustments To Reconcile Net Income	8.75	8.81	8.16	8.25	6.86	4.88	4.66	4.04	3.98	12
Changes in Operating Assets and Liabilities, net	-15	-7.29	-2.69	1.56	-1.52	1.85	-1.67	-8.41	-6.09	1.00
Net Cash From Investing Activities	3.42	5.76	22	3.76	5.01	4.60	-10	-80	-64	-5.86
Net Cash From Continuing Investing Activities	3.42	5.76	22	3.76	5.01	4.60	-10	-80	-64	-5.86
Purchase of Property, Plant & Equipment	-3.07	-2.86	-1.73	-3.93	-2.25	-3.50	-4.23	-1.48	-2.33	-5.86
Purchase of Investments	-19	-24	-	-29	-30	-19	-21	-100	-63	-
Sale and/or Maturity of Investments	25	33	24	36	37	27	35	21	1.73	-
Net Cash From Financing Activities	0.03	0.01	0.31	-0.19	0.17	0.16	1.18	108	0.30	0.35
Net Cash From Continuing Financing Activities	0.03	0.01	0.31	-0.19	0.17	0.16	1.18	108	0.30	0.35
Other Financing Activities, net	0.03	0.01	0.31	-0.19	0.17	0.16	1.18	0.35	-34	0.35
Cash Interest Paid	1.22	1.24	1.17	1.32	1.30	1.30	1.28	1.29	1.31	1.19

This table presents Treace Medical Concepts' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	217	252	159
Total Current Assets	161	198	133
Cash & Equivalents	11	13	19
Short-Term Investments	64	110	62
Accounts Receivable	41	38	29
Inventories, net	39	29	19
Prepaid Expenses	5.67	7.85	3.62
Plant, Property, & Equipment, net	26	22	15
Total Noncurrent Assets	30	31	10
Goodwill	13	13	0.00
Intangible Assets	8.08	9.03	0.00
Other Noncurrent Operating Assets	8.85	9.41	10
Total Liabilities & Shareholders' Equity	217	252	159
Total Liabilities	104	114	98
Total Current Liabilities	35	45	30
Accounts Payable	11	12	8.67
Accrued Expenses	17	21	14
Current Employee Benefit Liabilities	6.58	7.55	7.67
Other Current Liabilities	0.51	4.43	0.34
Total Noncurrent Liabilities	69	69	68
Long-Term Debt	53	53	53
Other Noncurrent Operating Liabilities	16	16	16
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	113	138	61
Total Preferred & Common Equity	113	138	61
Preferred Stock	0.00	0.00	0.00
Total Common Equity	113	138	61
Common Stock	303	272	145
Retained Earnings	-190	-134	-85
Treasury Stock	-0.28	-0.01	0.00
Accumulated Other Comprehensive Income / (Loss)	0.10	0.16	-0.03

This table presents Treace Medical Concepts' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	213	226	243	240	250	249	156
Total Current Assets	158	172	187	187	198	223	128
Cash & Equivalents	12	18	9.33	7.28	12	30	89
Short-Term Investments	71	77	101	115	127	141	-
Accounts Receivable	24	26	30	25	27	25	19
Inventories, net	44	41	36	29	26	23	17
Prepaid Expenses	7.02	9.67	11	11	5.28	4.59	4.01
Plant, Property, & Equipment, net	25	24	25	22	19	16	14
Total Noncurrent Assets	30	30	31	32	32	10	14
Goodwill	13	13	13	13	13	-	-
Intangible Assets	8.31	8.55	8.79	9.26	9.50	-	-
Other Noncurrent Operating Assets	9.03	8.92	9.21	9.61	9.80	10	14
Total Liabilities & Shareholders' Equity	213	226	243	240	250	249	156
Total Liabilities	108	114	116	103	100	92	94
Total Current Liabilities	38	44	47	33	30	23	23
Accounts Payable	19	18	21	8.68	8.15	5.08	7.88
Accrued Expenses	13	20	21	14	13	14	9.32
Current Employee Benefit Liabilities	5.60	6.19	4.20	5.07	5.37	3.30	5.05
Other Current Liabilities	0.57	0.52	1.02	5.19	3.78	-	0.33
Total Noncurrent Liabilities	70	69	69	69	70	68	72
Long-Term Debt	53	53	53	53	53	53	53
Other Noncurrent Operating Liabilities	17	16	16	16	17	15	19
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	105	112	126	138	150	158	62
Total Preferred & Common Equity	105	112	126	138	150	158	62
Preferred Stock	0.00	0.00	0.00	0.00	-	-	0.00
Total Common Equity	105	112	126	138	150	158	62
Common Stock	294	287	279	266	261	256	143
Retained Earnings	-189	-174	-153	-128	-110	-98	-80
Treasury Stock	-0.25	-0.25	-0.25	-	-	-	-
Accumulated Other Comprehensive Income / (Loss)	0.19	-0.03	0.07	-0.15	-0.22	-0.06	-

This table displays calculated financial ratios and metrics derived from Treace Medical Concepts' official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	11.89%	31.92%	50.22%
EBITDA Growth	-2.23%	-43.00%	-110.85%
EBIT Growth	-8.52%	-45.91%	-113.49%
NOPAT Growth	-8.28%	-47.60%	-111.05%
Net Income Growth	-12.55%	-15.68%	-108.33%
EPS Growth	-11.11%	-5.19%	-79.07%
Operating Cash Flow Growth	-7.50%	-12.81%	-78.26%
Free Cash Flow Firm Growth	13.94%	-80.42%	-174.53%
Invested Capital Growth	33.61%	111.79%	92.64%
Revenue Q/Q Growth	3.20%	7.12%	13.01%
EBITDA Q/Q Growth	12.79%	-6.03%	6.37%
EBIT Q/Q Growth	10.37%	-6.82%	4.59%
NOPAT Q/Q Growth	10.56%	-6.82%	5.68%
Net Income Q/Q Growth	9.39%	-3.92%	4.90%
EPS Q/Q Growth	9.09%	-2.53%	7.23%
Operating Cash Flow Q/Q Growth	-14.61%	14.56%	-5.53%
Free Cash Flow Firm Q/Q Growth	-22.79%	5.63%	-13.91%
Invested Capital Q/Q Growth	20.15%	-1.29%	21.67%
Profitability Metrics	-	-	-
Gross Margin	80.37%	81.20%	82.00%
EBITDA Margin	-23.04%	-25.22%	-23.26%
Operating Margin	-26.60%	-27.48%	-24.57%
EBIT Margin	-26.66%	-27.48%	-24.85%
Profit (Net Income) Margin	-26.63%	-26.47%	-30.19%
Tax Burden Percent	99.21%	99.31%	100.00%
Interest Burden Percent	100.68%	96.97%	121.47%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-49.26%	-72.19%	-100.39%
ROIC Less NNEP Spread (ROIC-NNEP)	-13.04%	-44.79%	-65.30%
Return on Net Nonoperating Assets (RNNOA)	4.81%	22.28%	44.64%
Return on Equity (ROE)	-44.45%	-49.91%	-55.75%
Cash Return on Invested Capital (CROIC)	-78.04%	-143.90%	-163.70%
Operating Return on Assets (OROA)	-23.80%	-25.03%	-23.51%
Return on Assets (ROA)	-23.77%	-24.10%	-28.56%
Return on Common Equity (ROCE)	-44.45%	-49.91%	-55.73%
Return on Equity Simple (ROE_SIMPLE)	-49.38%	-35.91%	-70.73%
Net Operating Profit after Tax (NOPAT)	-39	-36	-24
NOPAT Margin	-18.62%	-19.24%	-17.20%
Net Nonoperating Expense Percent (NNEP)	-36.22%	-27.40%	-35.09%
Return On Investment Capital (ROIC_SIMPLE)	-23.45%	-18.85%	-21.54%
Cost of Revenue to Revenue	19.63%	18.80%	18.00%
SG&A Expenses to Revenue	26.61%	25.13%	23.27%
R&D to Revenue	9.83%	8.25%	9.58%
Operating Expenses to Revenue	106.82%	108.50%	106.57%
Earnings before Interest and Taxes (EBIT)	-56	-51	-35
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-48	-47	-33
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	4.11	5.70	21.08
Price to Tangible Book Value (P/TBV)	5.04	6.77	21.08
Price to Revenue (P/Rev)	2.21	4.20	9.00
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	4.87	10.57	39.00
Enterprise Value to Revenue (EV/Rev)	2.11	3.83	8.79
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.47	0.38	0.87
Long-Term Debt to Equity	0.47	0.38	0.87
Financial Leverage	-0.37	-0.50	-0.68
Leverage Ratio	1.87	2.07	1.95
Compound Leverage Factor	1.88	2.01	2.37
Debt to Total Capital	32.07%	27.76%	46.55%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	32.07%	27.76%	46.55%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	67.93%	72.24%	53.45%
Debt to EBITDA	-1.11	-1.12	-1.60
Net Debt to EBITDA	0.46	1.49	0.87
Long-Term Debt to EBITDA	-1.11	-1.12	-1.60
Debt to NOPAT	-1.37	-1.47	-2.16
Net Debt to NOPAT	0.57	1.95	1.17
Long-Term Debt to NOPAT	-1.37	-1.47	-2.16
Altman Z-Score	2.26	4.19	7.97
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.03%
Liquidity Ratios	-	-	-
Current Ratio	4.62	4.40	4.41
Quick Ratio	3.34	3.58	3.65
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-62	-72	-40
Operating Cash Flow to CapEx	-320.60%	-301.75%	-206.55%
Free Cash Flow to Firm to Interest Expense	-11.75	-13.89	-4.48
Operating Cash Flow to Interest Expense	-7.07	-6.69	-3.45
Operating Cash Flow Less CapEx to Interest Expense	-9.28	-8.91	-5.12
Efficiency Ratios	-	-	-
Asset Turnover	0.89	0.91	0.95
Accounts Receivable Turnover	5.31	5.56	5.94
Inventory Turnover	1.20	1.45	1.71
Fixed Asset Turnover	8.68	9.94	15.60
Accounts Payable Turnover	3.68	3.43	4.01
Days Sales Outstanding (DSO)	68.75	65.60	61.46
Days Inventory Outstanding (DIO)	304.22	251.98	213.66
Days Payable Outstanding (DPO)	99.29	106.36	90.95
Cash Conversion Cycle (CCC)	273.68	211.22	184.16
Capital & Investment Metrics	-	-	-
Invested Capital	91	68	32
Invested Capital Turnover	2.65	3.75	5.84
Increase / (Decrease) in Invested Capital	23	36	15
Enterprise Value (EV)	441	716	1,247
Market Capitalization	463	786	1,276
Book Value per Share	$1.81	$2.24	$1.09
Tangible Book Value per Share	$1.48	$1.88	$1.09
Total Capital	166	191	113
Total Debt	53	53	53
Total Long-Term Debt	53	53	53
Net Debt	-22	-70	-29
Capital Expenditures (CapEx)	12	11	15
Debt-free, Cash-free Net Working Capital (DFCFNWC)	51	30	22
Debt-free Net Working Capital (DFNWC)	126	153	103
Net Working Capital (NWC)	126	153	103
Net Nonoperating Expense (NNE)	17	14	18
Net Nonoperating Obligations (NNO)	-22	-70	-29
Total Depreciation and Amortization (D&A)	7.57	4.24	2.25
Debt-free, Cash-free Net Working Capital to Revenue	24.26%	16.10%	15.44%
Debt-free Net Working Capital to Revenue	60.41%	81.94%	72.73%
Net Working Capital to Revenue	60.41%	81.94%	72.73%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($0.90)	($0.81)	($0.77)
Adjusted Weighted Average Basic Shares Outstanding	62.11M	60.85M	55.28M
Adjusted Diluted Earnings per Share	($0.90)	($0.81)	($0.77)
Adjusted Weighted Average Diluted Shares Outstanding	62.11M	60.85M	55.28M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	62.62M	61.76M	61.16M
Normalized Net Operating Profit after Tax (NOPAT)	-39	-36	-24
Normalized NOPAT Margin	-18.62%	-19.24%	-17.20%
Pre Tax Income Margin	-26.84%	-26.65%	-30.19%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-10.62	-9.95	-3.97
NOPAT to Interest Expense	-7.42	-6.97	-2.75
EBIT Less CapEx to Interest Expense	-12.82	-12.17	-5.64
NOPAT Less CapEx to Interest Expense	-9.62	-9.18	-4.42
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Treace Medical Concepts' official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	10.44%	10.62%	5.96%	21.12%	25.00%	23.30%	40.00%	45.26%	48.84%	52.90%
EBITDA Growth	128.04%	20.56%	-58.88%	-32.24%	-101.98%	-53.43%	26.92%	-67.77%	50.15%	-106.37%
EBIT Growth	91.23%	15.01%	-63.20%	-37.53%	-93.94%	-57.43%	24.27%	-68.58%	37.52%	-107.29%
NOPAT Growth	96.99%	15.06%	-63.82%	-37.69%	-93.94%	-57.43%	-9.38%	-70.16%	37.52%	-107.29%
Net Income Growth	92.02%	12.33%	-72.81%	-38.81%	-42.36%	-44.41%	28.80%	-48.89%	33.34%	-89.05%
EPS Growth	90.00%	10.71%	-70.00%	-30.43%	-25.00%	-27.27%	35.48%	-43.75%	42.86%	-83.33%
Operating Cash Flow Growth	-890.79%	-24.48%	-66.73%	58.16%	109.93%	-27.13%	21.11%	-138.35%	-42.80%	19.23%
Free Cash Flow Firm Growth	43.43%	68.44%	56.01%	-28.30%	-127.18%	-222.83%	-168.44%	-195.06%	-160.35%	19.37%
Invested Capital Growth	33.61%	9.77%	10.91%	70.27%	111.79%	161.04%	178.52%	129.91%	92.64%	52.54%
Revenue Q/Q Growth	52.39%	1.42%	-13.02%	-17.85%	52.64%	-2.85%	-0.57%	-15.22%	50.56%	10.30%
EBITDA Q/Q Growth	111.34%	32.45%	-13.67%	-222.19%	67.89%	-35.09%	5.39%	-392.09%	75.61%	35.65%
EBIT Q/Q Growth	96.07%	28.91%	-13.48%	-176.76%	61.94%	-36.52%	4.37%	-290.28%	69.10%	34.33%
NOPAT Q/Q Growth	98.65%	29.22%	-12.73%	-179.68%	61.94%	-36.52%	5.26%	-293.94%	69.10%	5.15%
Net Income Q/Q Growth	96.74%	27.57%	-13.55%	-197.34%	64.15%	-42.78%	8.79%	-204.94%	63.64%	29.60%
EPS Q/Q Growth	96.00%	26.47%	-13.33%	-200.00%	64.29%	-40.00%	13.04%	-187.50%	63.64%	29.03%
Operating Cash Flow Q/Q Growth	64.47%	14.79%	-92.45%	-1,457.33%	105.59%	-14.13%	51.71%	-222.12%	28.40%	29.18%
Free Cash Flow Firm Q/Q Growth	-32.46%	20.93%	47.84%	-3.56%	26.10%	-10.21%	-52.11%	-83.37%	-5.02%	8.36%
Invested Capital Q/Q Growth	20.15%	7.24%	1.13%	2.54%	-1.29%	8.36%	55.25%	27.54%	21.67%	15.61%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	80.74%	80.14%	80.25%	80.19%	81.56%	80.38%	81.71%	80.95%	81.87%	81.58%
EBITDA Margin	2.17%	-29.16%	-43.78%	-33.50%	-8.54%	-40.60%	-29.20%	-30.68%	-5.29%	-32.63%
Operating Margin	-0.30%	-33.57%	-48.10%	-37.11%	-10.90%	-43.72%	-31.11%	-32.65%	-7.03%	-34.24%
EBIT Margin	-0.87%	-33.59%	-47.92%	-36.73%	-10.90%	-43.72%	-31.11%	-32.35%	-7.03%	-34.24%
Profit (Net Income) Margin	-0.73%	-34.07%	-47.70%	-36.54%	-10.10%	-42.99%	-29.25%	-31.89%	-8.87%	-36.71%
Tax Burden Percent	49.60%	99.81%	99.85%	100.67%	96.56%	99.87%	99.23%	100.00%	54.30%	100.37%
Interest Burden Percent	169.75%	101.62%	99.70%	98.84%	95.92%	98.46%	94.74%	98.58%	232.34%	106.80%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-0.55%	-66.22%	-100.07%	-92.37%	-28.63%	-112.63%	-84.49%	-121.01%	-28.71%	-138.22%
ROIC Less NNEP Spread (ROIC-NNEP)	0.22%	-56.57%	-90.36%	-86.16%	-25.53%	-103.02%	-79.86%	-116.91%	-24.97%	-130.97%
Return on Net Nonoperating Assets (RNNOA)	-0.08%	23.02%	44.31%	52.71%	12.70%	54.14%	48.85%	88.91%	17.07%	95.24%
Return on Equity (ROE)	-0.63%	-43.20%	-55.77%	-39.67%	-15.93%	-58.48%	-35.64%	-32.10%	-11.64%	-42.98%
Cash Return on Invested Capital (CROIC)	-78.04%	-69.87%	-78.42%	-123.89%	-143.90%	-160.22%	-162.05%	-175.67%	-163.70%	-160.44%
Operating Return on Assets (OROA)	-0.77%	-30.06%	-39.99%	-29.27%	-9.93%	-38.49%	-25.44%	-25.34%	-6.65%	-29.23%
Return on Assets (ROA)	-0.65%	-30.49%	-39.81%	-29.13%	-9.19%	-37.85%	-23.92%	-24.98%	-8.39%	-31.34%
Return on Common Equity (ROCE)	-0.63%	-43.20%	-55.77%	-39.66%	-15.93%	-58.48%	-35.64%	-32.09%	-11.64%	-42.98%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-58.65%	-56.79%	-43.32%	0.00%	-34.57%	-28.19%	-29.97%	0.00%	-72.38%
Net Operating Profit after Tax (NOPAT)	-0.14	-11	-15	-13	-4.75	-12	-9.14	-9.64	-2.45	-7.92
NOPAT Margin	-0.21%	-23.50%	-33.67%	-25.98%	-7.63%	-30.60%	-21.78%	-22.85%	-4.92%	-23.97%
Net Nonoperating Expense Percent (NNEP)	-0.77%	-9.65%	-9.71%	-6.21%	-3.11%	-9.60%	-4.62%	-4.10%	-3.74%	-7.26%
Return On Investment Capital (ROIC_SIMPLE)	-0.09%	-	-	-	-2.49%	-	-	-	-2.16%	-
Cost of Revenue to Revenue	19.26%	19.86%	19.75%	19.81%	18.44%	19.62%	18.29%	19.05%	18.13%	18.42%
SG&A Expenses to Revenue	19.81%	30.00%	31.98%	28.10%	21.62%	31.13%	23.91%	25.75%	20.91%	26.97%
R&D to Revenue	7.58%	11.01%	11.60%	10.29%	6.67%	10.67%	8.40%	8.09%	7.53%	11.49%
Operating Expenses to Revenue	80.87%	113.66%	128.09%	117.15%	92.11%	124.04%	112.59%	113.60%	88.90%	115.82%
Earnings before Interest and Taxes (EBIT)	-0.60	-15	-21	-19	-6.78	-18	-13	-14	-3.50	-11
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	1.49	-13	-19	-17	-5.31	-17	-12	-13	-2.63	-11
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.11	3.44	3.68	6.37	5.70	5.85	10.46	9.78	21.08	19.66
Price to Tangible Book Value (P/TBV)	5.04	4.31	4.54	7.68	6.77	6.97	12.29	9.78	21.08	19.66
Price to Revenue (P/Rev)	2.21	1.78	2.08	4.11	4.20	4.62	9.40	9.94	9.00	9.74
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	4.87	4.40	5.27	10.77	10.57	10.75	23.40	34.87	39.00	45.14
Enterprise Value to Revenue (EV/Rev)	2.11	1.63	1.87	3.82	3.83	4.22	8.88	9.18	8.79	9.46
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.47	0.51	0.47	0.42	0.38	0.38	0.35	0.33	0.87	0.85
Long-Term Debt to Equity	0.47	0.51	0.47	0.42	0.38	0.38	0.35	0.33	0.87	0.85
Financial Leverage	-0.37	-0.41	-0.49	-0.61	-0.50	-0.53	-0.61	-0.76	-0.68	-0.73
Leverage Ratio	1.87	1.87	1.82	1.73	2.07	1.98	1.84	1.62	1.95	1.84
Compound Leverage Factor	3.17	1.90	1.81	1.71	1.99	1.95	1.75	1.60	4.54	1.97
Debt to Total Capital	32.07%	33.66%	32.16%	29.58%	27.76%	27.74%	26.06%	25.09%	46.55%	45.84%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	32.07%	33.66%	32.16%	29.58%	27.76%	27.74%	26.06%	25.09%	46.55%	45.84%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	67.93%	66.34%	67.84%	70.42%	72.24%	72.26%	73.94%	74.88%	53.45%	54.16%
Debt to EBITDA	-1.11	-0.96	-0.91	-1.03	-1.12	-1.19	-1.36	-1.39	-1.60	-1.49
Net Debt to EBITDA	0.46	0.53	0.71	1.11	1.49	1.56	2.24	3.11	0.87	1.02
Long-Term Debt to EBITDA	-1.11	-0.96	-0.91	-1.03	-1.12	-1.19	-1.36	-1.39	-1.60	-1.49
Debt to NOPAT	-1.37	-1.22	-1.17	-1.34	-1.47	-1.57	-1.81	-1.86	-2.16	-2.04
Net Debt to NOPAT	0.57	0.68	0.92	1.44	1.95	2.05	2.97	4.16	1.17	1.39
Long-Term Debt to NOPAT	-1.37	-1.22	-1.17	-1.34	-1.47	-1.57	-1.81	-1.86	-2.16	-2.04
Altman Z-Score	3.10	2.15	2.34	4.52	4.78	5.23	10.13	10.95	8.62	8.44
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.02%	0.00%	0.00%	0.00%	0.04%	0.03%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.62	4.12	3.86	3.98	4.40	5.64	6.60	9.58	4.41	5.66
Quick Ratio	3.34	2.80	2.71	2.98	3.58	4.44	5.55	8.41	3.65	4.74
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-23	-17	-22	-42	-41	-55	-50	-33	-18	-17
Operating Cash Flow to CapEx	-136.86%	-413.62%	-803.76%	-183.88%	23.67%	-271.72%	-197.00%	-1,167.73%	-229.76%	-127.76%
Free Cash Flow to Firm to Interest Expense	-17.44	-13.18	-16.68	-31.85	-31.06	-42.29	-38.79	-25.44	-1.74	-14.27
Operating Cash Flow to Interest Expense	-3.20	-9.02	-10.59	-5.48	0.41	-7.34	-6.50	-13.43	-0.52	-6.29
Operating Cash Flow Less CapEx to Interest Expense	-5.54	-11.20	-11.91	-8.46	-1.32	-10.04	-9.80	-14.58	-0.75	-11.21
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.89	0.90	0.83	0.80	0.91	0.88	0.82	0.78	0.95	0.85
Accounts Receivable Turnover	5.31	8.25	7.52	7.07	5.56	8.02	7.64	7.49	5.94	8.27
Inventory Turnover	1.20	1.08	1.14	1.28	1.45	1.42	1.57	1.69	1.71	1.61
Fixed Asset Turnover	8.68	8.69	9.09	9.70	9.94	9.79	11.85	15.57	15.60	15.33
Accounts Payable Turnover	3.68	2.88	2.93	2.84	3.43	3.95	5.48	6.67	4.01	4.24
Days Sales Outstanding (DSO)	68.75	44.24	48.53	51.62	65.60	45.49	47.80	48.70	61.46	44.12
Days Inventory Outstanding (DIO)	304.22	338.37	320.44	285.87	251.98	257.06	232.49	215.80	213.66	226.42
Days Payable Outstanding (DPO)	99.29	126.81	124.69	128.42	106.36	92.33	66.58	54.70	90.95	86.10
Cash Conversion Cycle (CCC)	273.68	255.80	244.28	209.07	211.22	210.22	213.72	209.81	184.16	184.43
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	91	75	70	69	68	69	63	41	32	26
Invested Capital Turnover	2.65	2.82	2.97	3.56	3.75	3.68	3.88	5.29	5.84	5.77
Increase / (Decrease) in Invested Capital	23	6.71	6.91	29	36	42	41	23	15	9.06
Enterprise Value (EV)	441	331	370	748	716	738	1,482	1,423	1,247	1,187
Market Capitalization	463	361	412	805	786	807	1,569	1,541	1,276	1,223
Book Value per Share	$1.81	$1.69	$1.81	$2.05	$2.24	$2.24	$2.45	$2.58	$1.09	$1.12
Tangible Book Value per Share	$1.48	$1.35	$1.46	$1.70	$1.88	$1.88	$2.08	$2.58	$1.09	$1.12
Total Capital	166	158	165	179	191	191	203	210	113	115
Total Debt	53	53	53	53	53	53	53	53	53	53
Total Long-Term Debt	53	53	53	53	53	53	53	53	53	53
Net Debt	-22	-30	-42	-57	-70	-69	-87	-118	-29	-36
Capital Expenditures (CapEx)	3.07	2.86	1.73	3.93	2.25	3.50	4.23	1.48	2.33	5.86
Debt-free, Cash-free Net Working Capital (DFCFNWC)	51	37	32	30	30	32	29	29	22	17
Debt-free Net Working Capital (DFNWC)	126	119	127	140	153	154	168	200	103	105
Net Working Capital (NWC)	126	119	127	140	153	154	168	200	103	105
Net Nonoperating Expense (NNE)	0.36	4.77	6.24	5.40	1.53	5.05	3.13	3.81	1.96	4.21
Net Nonoperating Obligations (NNO)	-22	-30	-42	-57	-70	-69	-87	-117	-29	-36
Total Depreciation and Amortization (D&A)	2.09	2.00	1.84	1.65	1.47	1.27	0.80	0.70	0.87	0.53
Debt-free, Cash-free Net Working Capital to Revenue	24.26%	18.01%	16.15%	15.48%	16.10%	18.22%	17.13%	18.82%	15.44%	13.37%
Debt-free Net Working Capital to Revenue	60.41%	58.83%	64.02%	71.59%	81.94%	88.16%	100.66%	128.94%	72.73%	83.92%
Net Working Capital to Revenue	60.41%	58.83%	64.02%	71.59%	81.94%	88.16%	100.66%	128.94%	72.73%	83.92%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.01)	($0.25)	($0.34)	($0.30)	($0.10)	($0.28)	($0.20)	($0.23)	($0.08)	($0.22)
Adjusted Weighted Average Basic Shares Outstanding	62.11M	62.23M	62.08M	61.79M	60.85M	61.56M	61.38M	58.72M	55.28M	55.43M
Adjusted Diluted Earnings per Share	($0.01)	($0.25)	($0.34)	($0.30)	($0.10)	($0.28)	($0.20)	($0.23)	($0.08)	($0.22)
Adjusted Weighted Average Diluted Shares Outstanding	62.11M	62.23M	62.08M	61.79M	60.85M	61.56M	61.38M	58.72M	55.28M	55.43M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	62.62M	62.30M	62.19M	62.01M	61.76M	61.68M	61.54M	61.33M	61.16M	55.50M
Normalized Net Operating Profit after Tax (NOPAT)	-0.14	-11	-15	-13	-4.75	-12	-9.14	-9.64	-2.45	-7.92
Normalized NOPAT Margin	-0.21%	-23.50%	-33.67%	-25.98%	-7.63%	-30.60%	-21.78%	-22.85%	-4.92%	-23.97%
Pre Tax Income Margin	-1.47%	-34.13%	-47.77%	-36.30%	-10.46%	-43.04%	-29.48%	-31.89%	-16.33%	-36.57%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-0.45	-11.53	-16.24	-14.25	-5.20	-13.75	-10.18	-10.62	-0.34	-9.51
NOPAT to Interest Expense	-0.11	-8.07	-11.41	-10.08	-3.64	-9.62	-7.13	-7.50	-0.24	-6.66
EBIT Less CapEx to Interest Expense	-2.79	-13.71	-17.55	-17.23	-6.92	-16.45	-13.48	-11.77	-0.57	-14.43
NOPAT Less CapEx to Interest Expense	-2.45	-10.25	-12.73	-13.06	-5.36	-12.33	-10.43	-8.65	-0.47	-11.58
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Treace Medical Concepts' Financials

When does Treace Medical Concepts's financial year end?

According to the most recent income statement we have on file, Treace Medical Concepts' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Treace Medical Concepts' net income changed over the last 2 years?

Treace Medical Concepts' net income appears to be on an upward trend, with a most recent value of -$55.74 million in 2024, rising from -$42.82 million in 2022. The previous period was -$49.53 million in 2023. See where experts think Treace Medical Concepts is headed by visiting Treace Medical Concepts' forecast page.

What is Treace Medical Concepts's operating income?

Treace Medical Concepts's total operating income in 2024 was -$55.69 million, based on the following breakdown:

Total Gross Profit: $168.26 million
Total Operating Expenses: $223.63 million

How has Treace Medical Concepts revenue changed over the last 2 years?

Over the last 2 years, Treace Medical Concepts' total revenue changed from $141.84 million in 2022 to $209.36 million in 2024, a change of 47.6%.

How much debt does Treace Medical Concepts have?

Treace Medical Concepts' total liabilities were at $104.20 million at the end of 2024, a 8.6% decrease from 2023, and a 5.8% increase since 2022.

How much cash does Treace Medical Concepts have?

In the past 2 years, Treace Medical Concepts' cash and equivalents has ranged from $11.35 million in 2024 to $19.47 million in 2022, and is currently $11.35 million as of their latest financial filing in 2024.

How has Treace Medical Concepts' book value per share changed over the last 2 years?

Over the last 2 years, Treace Medical Concepts' book value per share changed from 1.09 in 2022 to 1.81 in 2024, a change of 66.2%.

Related Companies

This page (NASDAQ:TMCI) was last updated on 5/29/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Treace Medical Concepts (TMCI) Financials

Frequently Asked Questions About Treace Medical Concepts' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Treace Medical Concepts (TMCI) Financials

Annual Income Statements for Treace Medical Concepts

Quarterly Income Statements for Treace Medical Concepts

Annual Cash Flow Statements for Treace Medical Concepts

Quarterly Cash Flow Statements for Treace Medical Concepts

Annual Balance Sheets for Treace Medical Concepts

Quarterly Balance Sheets for Treace Medical Concepts

Annual Metrics And Ratios for Treace Medical Concepts

Quarterly Metrics And Ratios for Treace Medical Concepts

Frequently Asked Questions About Treace Medical Concepts' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools